Filter Your Search

Clinical Trial Search

Keyword

Principal Investigator

Condition/Disease

For Healthcare Professionals

At Henry Ford Health System we serve a triple mission of Clinical Care, Research and Education. It is this triple mission that drives how we care for our patients, how we interact with referring physicians, how we work to innovate healthcare and how we train future physicians.

Learn More

Clinical Trials Search Results

LOXO-RET-17001: A Phase 1/2 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001)

Principal Investigator:Ding Wang, MD

Status: Accepting Participants

Contact Phone: 1-888-734-5322

Contact Email: CTOResearch@hfhs.org

MK4830-001: A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab for Participants With Advanced Solid Tumors

Principal Investigator:Ding Wang, MD

Status: Open

Contact Phone: (313) 916-7450

Contact Email: CTOResearch@hfhs.org

PTC-299-HEM-001-LEU: Phase 1b Study of PTC299 in Relapsed/Refractory Acute Leukemias

Principal Investigator:Ahmad H Mattour, MD

Status: Accepting Participants

Contact Phone: (888) 734-5322

Contact Email: CTOResearch@hfhs.org

GBM 001: An Open-Label, Multi-Center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination with REGN2810 in Subjects with Newly-Diagnosed Glioblastoma

Principal Investigator:Tobias Walbert, MD

Status: Accepting Participants

Contact Phone: (313) 916-3731

Contact Email: CTOResearch@hfhs.org

MS200527-0018 A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study Examining the Safety and Efficacy of M2951 in Subjects with Systemic Lupus Erythematosus (SLE)

Principal Investigator:Kathleen M Maksimowicz-Mckinnon, DO

Status: Accepting Participants

Contact Phone: (313) 916-9328

Contact Email: Rheumatologyresearch@hfhs.org

MS100015-0019: Open-label, Phase I, Dose Escalation Trial, investigating Methionine Aminopeptidase 2 Inhibitor M8891 in Subjects with Advanced Solid Tumors

Principal Investigator:Ding Wang, MD

Status: Accepting Participants

Contact Phone: (313)916-1784

Contact Email: CTOResearch@hfhs.org

Catalyst MSK 002: A Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Amifampridine Phosphate in Patients with MuSK Antibody Positive Myasthenia Gravis, and a Sample of AChR Antibody Positive Myasthenia Gravis Patients

Principal Investigator:Kavita M Grover, MD

Status: Accepting Participants

Contact Phone: (313) 916-4123

Contact Email: NeurologyResearch@hfhs.org

P2B001-003, A Phase 3, Twelve-week, Multi-Center, Randomized, Double-Blind, active-controlled, Parallel Group Study to Determine the Safety, Tolerability, and Efficacy of P2B001 Compared to its Individual Components in Subjects with Early Parkinson's Disease

Principal Investigator:Peter A Le Witt, MD

Status: Accepting Participants

Contact Phone: (248) 661-6540

Contact Email: parkinsons@hfhs.org

RX-5902-P1-01: A Multi-Center, Dose Finding, Open Label, Phase 1 Study of RX-5902 in Subjects With Advanced or Metastatic Solid Tumors (Stage 1 and Stage 2 of Phase 2)

Principal Investigator:Ding Wang, MD

Status: Open

Contact Phone: (313) 916-7450

Contact Email: CTOResearch@hfhs.org

ASTX660-01: Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas

Principal Investigator:Ding Wang, MD

Status: Accepting Participants

Contact Phone: (313) 916-1784

Contact Email: CTORsearch@hfhs.org

Page 1 of 33 | Results 1 - 10 of 323

Featured Locations Search All Locations

Browse Locations by Type

Frequently Searched ServicesSearch All Services

Browse Services by A-Z

Log in to MyChart

Connect with Us

Resources

Research & Education

Clinical Trial Search

For Healthcare Professionals

Clinical Trials Search Results

LOXO-RET-17001: A Phase 1/2 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001)

MK4830-001: A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab for Participants With Advanced Solid Tumors

PTC-299-HEM-001-LEU: Phase 1b Study of PTC299 in Relapsed/Refractory Acute Leukemias

GBM 001: An Open-Label, Multi-Center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination with REGN2810 in Subjects with Newly-Diagnosed Glioblastoma

MS200527-0018 A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study Examining the Safety and Efficacy of M2951 in Subjects with Systemic Lupus Erythematosus (SLE)

MS100015-0019: Open-label, Phase I, Dose Escalation Trial, investigating Methionine Aminopeptidase 2 Inhibitor M8891 in Subjects with Advanced Solid Tumors

Catalyst MSK 002: A Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Amifampridine Phosphate in Patients with MuSK Antibody Positive Myasthenia Gravis, and a Sample of AChR Antibody Positive Myasthenia Gravis Patients

P2B001-003, A Phase 3, Twelve-week, Multi-Center, Randomized, Double-Blind, active-controlled, Parallel Group Study to Determine the Safety, Tolerability, and Efficacy of P2B001 Compared to its Individual Components in Subjects with Early Parkinson's Disease

RX-5902-P1-01: A Multi-Center, Dose Finding, Open Label, Phase 1 Study of RX-5902 in Subjects With Advanced or Metastatic Solid Tumors (Stage 1 and Stage 2 of Phase 2)

ASTX660-01: Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas